Pacific Biosciences

177 articles with Pacific Biosciences

• Invitae and Pacific Biosciences Collaborate to Develop Whole Genome Sequencing-Based Assays for Pediatric Epilepsy Diagnostics

  10/22/2020

  Invitae Corporation (NYSE: NVTA), a leading genetics company, and Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced a research collaboration focused on the investigation of clinically relevant molecular targets for use in the development of advanced diagnostic testing for epilepsy. To support this collaboration, In

• Pacific Biosciences Launches the Sequel IIe System to Accelerate Adoption of Highly Accurate HiFi SequencingNew system

  10/5/2020

  Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced the launch of the Sequel ® IIe System, the next instrument evolution based on the company’s Single Molecule, Real-Time (SMRT ® ) Sequencing technology. With increased computational capacity and on-instrument data processing, the new system can directly produce highly accurate long r

• Pacific Biosciences of California, Inc. Announces Pricing of Public Offering of Common Stock - Aug 12, 2020

  8/12/2020

  Pacific Biosciences of California, Inc. announced that it has priced its previously announced underwritten public offering of 19,430,000 shares of its common stock at a price to the public of $4.47 per share.

• Pacific Biosciences Announces New Chief Executive Officer

  8/7/2020

  Christian O. Henry Named Chief Executive Officer John F. Milligan, Ph.D. Named Chairman of the Board Ben Gong Named Interim CFO

• Pacific Biosciences and Asuragen Collaborate to Develop Assays for Carrier Screening and other Applications Based on SMRT Sequencing Technology and AmplideX PCR Chemistry

  8/3/2020

  Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, and Asuragen, a molecular diagnostics company delivering easy-to-use products for complex testing in ge

• Pacific Biosciences of California, Inc. Announces Second Quarter 2020 Financial Results

  8/3/2020

  Pacific Biosciences of California, Inc. announced financial results for its second quarter ended June 30, 2020.

• Pacific Biosciences of California, Inc. Second Quarter 2020 Financial Results Call

  7/24/2020

  Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Second Quarter 2020 Financial Results on Monday, August 3, 2020, at 4:30pm Eastern Time. The call will be webcast and may be accessed at Pacific Biosciences’ website at:  https://investor.pacificbiosciences.com/ . Date:  August 3, 2020 Time:  4:30pm ET Listen via Internet:  https://investor.pacificbiosciences.com/ Toll-

• Pacific Biosciences Announces Planned Retirement of CEO, Dr. Michael Hunkapiller

  6/10/2020

  Pacific Biosciences of California, Inc. (NASDAQ: PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that Michael Hunkapiller, Ph.D. is retiring as Chief Executive Officer and President by the end of the year.  Dr. Hunkapiller plans to remain on the Board of Directors.  The company als

• Pacific Biosciences of California, Inc. Announces First Quarter 2020 Financial Results

  5/6/2020

  Pacific Biosciences of California, Inc. announced financial results for its first quarter ended March 31, 2020.

• Pacific Biosciences of California, Inc. First Quarter 2020 Financial Results Call

  4/27/2020

  Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its First Quarter 2020 Financial Results on Wednesday, May 6, 2020, at 4:30pm Eastern Time. The call will be webcast and may be accessed at Pacific Biosciences’ website at:  https://investor.pacificbiosciences.com/ . Date:  May 6, 2020 Time:  4:30pm ET Listen via Internet:  https://investor.pacificbiosciences.com/ Toll-fre

• inqaba biotec acquires the first PacBio Sequel II System in Africa

  4/20/2020

  Deployment expands access to PacBio’s highly accurate long reads on the African continent for a variety of applications, from ethnic-specific reference genomes to COVID-19 research

• Pacific Biosciences Powers SARS-CoV-2 Research at Commercial, Academic and Government Labs

  4/8/2020

  LabCorp, UC San Diego and the National Institute of Allergy and Infectious Diseases are among the organizations utilizing PacBio’s highly accurate long-read sequencing technology to study SARS-CoV-2 and the related immune response to COVID-19 MENLO PARK, Calif., April 08, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that it is working with commercial, a

• Jury Invalidates PacBio's Patents in U.S. Patent Trial Against Oxford Nanopore

  3/18/2020

  After more than one week of evidence, a federal jury in Delaware found in favour of Oxford Nanopore and invalidated all four patents asserted by Pacific Biosciences in this litigation.

• Christian Henry Appointed Chairman of Pacific Biosciences’ Board of Directors

  3/5/2020

  Pacific Biosciences of California, Inc. announced that industry veteran Christian Henry has been appointed to serve as Chairman of its Board of Directors.

• Pacific Biosciences Announces Fourth Quarter and Annual 2019 Financial ResultsAnnual Revenue Increase of 16% Year Over Year

  2/6/2020

  Pacific Biosciences of California, Inc. announced financial results for its fourth quarter and year ended December 31, 2019, as attached.

• CORRECTION – Pacific Biosciences of California, Inc. Fourth Quarter 2019 Financial Results Call

  1/21/2020

  In a release issued earlier under the same headline by Pacific Biosciences of California, Inc., please note that the date in paragraph three should read February 6, 2020, not January 6, 2020, as previously stated.

• 

  Following Antitrust Concerns, Illumina and Pacific Bio Call Off $1.2 Billion Merger

  1/3/2020

  The two companies cited a lengthy regulatory approval process and “continued uncertainty” of the outcome of the merger as the primary reasons behind the termination of the deal.

• Illumina and Pacific Biosciences Announce Termination of Merger Agreement

  1/2/2020

  In accordance with the merger agreement, Illumina will pay Pacific Biosciences a termination fee of $98 million.

• 

  Top 10 Gene Sequencing Companies by Revenue

  11/29/2019

  The gene sequencing industry has really taken off in the years since the Human Genome Project’s rough draft was announced in June 2000.

• Pacific Biosciences of California, Inc. Announces Third Quarter 2019 Financial Results

  11/7/2019

  Pacific Biosciences of California, Inc. announced financial results for its third quarter ended September 30, 2019..